News | September 04, 2008

Dutch Medical Isotopes Unavailable Until End of October

September 4, 2008 - Cancer patients in Europe, and possibly worldwide, may face a longer wait for diagnostic tests and treatments as a nuclear reactor in the Netherlands that supplies medical isotopes extended its shutdown for potential safety reasons.

Nuclear Research and Consultancy Group, which operates the reactor in Petten, in northwestern Netherlands, said Wednesday it would not start up the reactor again before the end of October.

About 15 to 20 percent of Canada's medical isotopes come from overseas, including the Petten facility, according to Health Canada.

"The consequences of this further delay will have an impact on the medical isotope market," the Dutch company said in a statement.

"NRG will not produce any medical isotopes in the months September and October (until 25th of October). We have already informed our customers about the situation. We are assisting in the search for alternative supply routes."

NRG stopped activity at the reactor after air bubbles were discovered in its cooling system. The company has said there is no danger to the public or the environment.

The reactor is the second-biggest producer of medical isotopes worldwide after Atomic Energy of Canada Ltd.'s facility at Chalk River, ON. The Dutch reactor produces the majority of the world supply of isotopes of the element technetium, which give off radiation used in medical imaging and disease treatments.

Technetium-99m is used in 80 percent of diagnostic imaging that uses nuclear medicine technology, including imaging of the heart, kidney and brain. NRG-made isotopes account for seven million diagnostic tests per year in Europe and eight million per year in the U.S., according to the company.

Last week, AECL said that, given the problems in the Netherlands, the nuclear reactor at Chalk River, ON, could ramp up to meet Canada's demand for medical isotopes if required.

But MDS Nordion, a Canadian company that buys isotopes from AECL and sells them to pharmaceutical manufacturers, said: "MDS Nordion does not determine the allocation of medical isotopes to specific end users," such as hospitals in Canada or worldwide.

"We are concerned there is currently no reliable, long-term isotope supply solution to meet this growing demand. As a result, there is risk of isotope shortages recurring," MDS Nordion said in a statement last week.

In December 2007, unexpected problems during routine maintenance at Chalk River forced the reactor to be taken offline, causing a shortage of medical isotopes worldwide.

Source: cbcnews.ca
For more information: www.cbc.ca

Related Content

Avoiding contrast dyes for imaging tests not necessary if concerned about iodine allergy, peer-reviewed study concludes #MRI

Getty Images

News | Contrast Media Injectors | September 16, 2021
September 16, 2021 — FDB (First Databank), a leading provider of drug and medical device knowledge that helps healthc
PET, PET imaging, PET-CT, FDG PET, PET cancer assessment, pet scanner, nuclear imaging, molecular imaging

A PET-CT head and neck cancer scan showing various image reconstructions. The top left image is the separate CT scan showing the anatomy. The top right scan shows the fused PET and CT scans with false color added to help interpret the image. The bottom left scan is an initial FDG PET image showing tracer hot spots in the neck and a lymph node in the right jaw due to cancer. The right bottom image is a delayed enhancement scan showing tracer uptake over time, with normal hot spots in the bladder, kidneys, testicles and brain, which normally have higher metabolic activity. The low-grade gray shading of the anatomy is due to the normal cellular metabolism uptake of the FDG throughout the body. 

News | PET-CT | August 04, 2021
August 4, 2021 — PET/CT systems are exp
According to ARRS’ American Journal of Roentgenology (AJR), the resources required to warm iohexol 350 to body temperature before injection for computed tomography (CT) may not be warranted, given the lack of observed practical benefit.

Values represent number of patients, with percentage in parentheses and 95% CI in brackets (not reported for levels of severity of allergic/allergic-like reactions). 95% CIs were calculated using the Clopper-Pearson exact formula. For events with zero frequency, one-sided 97.5% CIs are provided.

News | Contrast Media | July 30, 2021
IQ-AI subsidiary Imaging Biometrics (IB) was awarded a U.S. patent for its artificial intelligence (AI) software technology that eliminates the need for gadolinium-based contrast agents (GBCAs) in medical imaging exams.
News | Contrast Media | June 30, 2021
June 30, 2021 – IQ-AI subsid
The contrast agents global market is expected to grow at a high single digit CAGR from 2020 to 2027 to reach $7,033.5 million by 2027 due to the increasing incidence and prevalence of chronic diseases and demand for diagnostic and interventional radiology procedures, increase in aging population, expansion of contrast agent indications, the growth of medical imaging in the emerging market, increasing research activities and favorable reimbursement

image courtesy of Guerbet

News | Contrast Media | May 03, 2021
Chemical substances that improve the visibility of specific organs, tissues, or blood vessels during a diagnostic or
Gadopiclenol is a high-relaxivity macrocyclic contrast agent used for magnetic resonance imaging (MRI)
News | Contrast Media | March 24, 2021
March 24, 2021 — Guerbet announced positive results from two...
(a) High-resolution 3D MRI brain vascular map using SAIO. Various blood vessels in the rat brain can be visualized. In addition to clinically important brain vessels including anterior cerebral artery, middle cerebral artery, posterior cerebral artery, fine vessel structures as thin as ~ 100 microns in diameter can be clearly visualized. (b) 3D MRI brain vascular map using Dotarem (gadolinium-based contrast agent). Resolution is low and microvessels are not visible. (c) For 3D reconstruction, multiple slice

(a) High-resolution 3D MRI brain vascular map using SAIO. Various blood vessels in the rat brain can be visualized. In addition to clinically important brain vessels including anterior cerebral artery, middle cerebral artery, posterior cerebral artery, fine vessel structures as thin as ~ 100 microns in diameter can be clearly visualized. (b) 3D MRI brain vascular map using Dotarem (gadolinium-based contrast agent). Resolution is low and microvessels are not visible. (c) For 3D reconstruction, multiple slices of MRI images of the rat heart were obtained after injection of SAIO. Rat coronary arteries (180 microns) which are 10 times thinner than human coronary arteries were successfully visualized. Coronary arteries supply blood to the heart muscle and the blockage or narrowing of such arteries causes myocardial infarction or angina, but visualizing these arteries was impossible due to the limited resolution of current MRI contrast agents. Image courtesy of Institute for Basic Science

News | Contrast Media | March 12, 2021
March 12, 2021 — Heart attack and stroke are the first and second leading causes of death in developed countries, res
Guerbet announced the launch of OptiProtect 3S, a new range of technical services for its injection solutions. OptiProtect 3S is designed to support imaging centers in the daily use and protection of their injection solutions.
News | Contrast Media Injectors | February 25, 2021
February 25, 2021 — Guerbet announced the launch of ...